Diazepinomicin

Drug Profile

Diazepinomicin

Alternative Names: AMO 01; BU-4664L; ECO 04601; ECO 4601; TLN 4601

Latest Information Update: 24 Aug 2016

Price : $50

At a glance

  • Originator Ecopia BioSciences
  • Developer AMO Pharma; BELLUS Health
  • Class Alkaloids; Antineoplastics; Benzodiazepinones; Small molecules
  • Mechanism of Action Apoptosis stimulants; Ras protein inhibitors; TSPO protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fragile X syndrome
  • Discontinued Glioblastoma

Most Recent Events

  • 11 Aug 2016 Discontinued - Phase-II for Glioblastoma in Canada (IV)
  • 11 Aug 2016 Discontinued - Phase-II for Glioblastoma in USA (IV)
  • 08 Jun 2016 Phase-I clinical trials in Fragile X syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top